Other studies looked at the role of some other genes, such as IGF1 cytosine adenine (CA) [52] and p53 [53], in BC risk, while a sequencing study from Qatar analyzed the role of ER 1 gene mutations on drugs binding affinity to ER [54]. The gene discussed is TP53; the disease is breast cancer.